Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Adds Three Executive Team Members
February 13, 2012 TUCSON, Ariz. — HTG Molecular , a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans , Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer,
Toggle Summary HTG/Sanofi US Annouce Biomarker Collaboration
HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine TUCSON, Ariz.
Toggle Summary HTG Molecular Diagnostics Hires Vice President of Medical Innovation
TUCSON, Ariz. (April 26, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Chris Roberts as vice president of medical innovation. Roberts joins HTG from Caris Life Sciences where he served as vice president of the oncology division
Toggle Summary Sam Rua HTG Molecular Diagnostics VP of Regulatory Affairs is Keynote Presenter at TIDES Conference
TUCSON, Ariz. (May 14, 2012) – Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide
Toggle Summary HTG Molecular Diagnostics Partners with John Wayne Cancer Institute to Commercialize Melanoma Signatures
TUCSON, Ariz. (June 1, 2012) – The John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California selected HTG Molecular Diagnostics as an exclusive commercialization partner for recently identified HTG melanoma signature assays which may be useful for diagnostic and

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

An amendment to the SC 13G filing

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities